Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer
Issued Date
2025-06-01
Resource Type
eISSN
20597029
Scopus ID
2-s2.0-105007476095
Journal Title
ESMO Open
Volume
10
Issue
6
Rights Holder(s)
SCOPUS
Bibliographic Citation
ESMO Open Vol.10 No.6 (2025)
Suggested Citation
Nag S., Ray Coquard I., Gupta S., Pathak A., Li N., Mulya Sari R., Harano K., Kim G.M., Ang S.F., Que F.V., Chay W.Y., Lai H.C., Ativitavas T., Tangjitgamol S., Lai C.H., Heong V.Y.M., Contreras Tolentino J., Ngu M.R., Yun J., Yunokawa M., Hanafi W.L.H., Li J., Smyth E., Yoshino T., Mehta J., Pentheroudakis G., Maheshwari A., Cervantes A., Basade M., Oaknin A. Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer. ESMO Open Vol.10 No.6 (2025). doi:10.1016/j.esmoop.2025.105125 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/110710
Title
Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer
Author(s)
Nag S.
Ray Coquard I.
Gupta S.
Pathak A.
Li N.
Mulya Sari R.
Harano K.
Kim G.M.
Ang S.F.
Que F.V.
Chay W.Y.
Lai H.C.
Ativitavas T.
Tangjitgamol S.
Lai C.H.
Heong V.Y.M.
Contreras Tolentino J.
Ngu M.R.
Yun J.
Yunokawa M.
Hanafi W.L.H.
Li J.
Smyth E.
Yoshino T.
Mehta J.
Pentheroudakis G.
Maheshwari A.
Cervantes A.
Basade M.
Oaknin A.
Ray Coquard I.
Gupta S.
Pathak A.
Li N.
Mulya Sari R.
Harano K.
Kim G.M.
Ang S.F.
Que F.V.
Chay W.Y.
Lai H.C.
Ativitavas T.
Tangjitgamol S.
Lai C.H.
Heong V.Y.M.
Contreras Tolentino J.
Ngu M.R.
Yun J.
Yunokawa M.
Hanafi W.L.H.
Li J.
Smyth E.
Yoshino T.
Mehta J.
Pentheroudakis G.
Maheshwari A.
Cervantes A.
Basade M.
Oaknin A.
Author's Affiliation
Neuberg Oncopath
Penang Adventist Hospital
MedPark Hospital
National Cancer Centre, Singapore
Sarawak General Hospital
Section of Medical Oncology
Cancer Care Clinic
Sahyadri Superspeciality Hospital
Breach Candy Hospital
European Society for Medical Oncology
Vall d‘Hebron Institut de Oncologia
Tan Tock Seng Hospital
Makati Medical Center
Homi Bhabha National Institute
Churchill Hospital
Rumah Sakit Kanker Dharmais
Chang Gung Memorial Hospital
Le Centre Régional de Lutte Contre le Cancer Léon Bérard
Tata Memorial Hospital
Yonsei Cancer Hospital
Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Sun Yat-Sen University Cancer Center
National Cancer Center Hospital East
Centro de Investigación Biomédica en Red de Cáncer
Soonchunhyang University, College of Medicine
Taipei Medical University Shuang-Ho Hospital
Vajira Hospital
Kindai University School of Medicine
Hospital Clinico Universitario de Valencia
Ramathibodi Hospital
Cancer Institute Hospital of Japan Foundation for Cancer Research
Penang Adventist Hospital
MedPark Hospital
National Cancer Centre, Singapore
Sarawak General Hospital
Section of Medical Oncology
Cancer Care Clinic
Sahyadri Superspeciality Hospital
Breach Candy Hospital
European Society for Medical Oncology
Vall d‘Hebron Institut de Oncologia
Tan Tock Seng Hospital
Makati Medical Center
Homi Bhabha National Institute
Churchill Hospital
Rumah Sakit Kanker Dharmais
Chang Gung Memorial Hospital
Le Centre Régional de Lutte Contre le Cancer Léon Bérard
Tata Memorial Hospital
Yonsei Cancer Hospital
Cancer Institute & Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Sun Yat-Sen University Cancer Center
National Cancer Center Hospital East
Centro de Investigación Biomédica en Red de Cáncer
Soonchunhyang University, College of Medicine
Taipei Medical University Shuang-Ho Hospital
Vajira Hospital
Kindai University School of Medicine
Hospital Clinico Universitario de Valencia
Ramathibodi Hospital
Cancer Institute Hospital of Japan Foundation for Cancer Research
Corresponding Author(s)
Other Contributor(s)
Abstract
The European Society for Medical Oncology (ESMO) Clinical Practice Guideline for the diagnosis, treatment and follow-up of patients with newly diagnosed and relapsed epithelial ovarian cancer (EOC), published in 2023, was adapted in July 2024, according to established standard methodology, to produce the Pan-Asian adapted ESMO consensus guideline for the management of Asian patients with EOC. The adapted guideline presented in this manuscript represents the consensus opinions reached by a panel of Asian experts in the treatment of patients with EOC representing the oncological societies of China, Indonesia, India, Japan, Korea, Malaysia, the Philippines, Singapore, Taiwan and Thailand, coordinated by ESMO and the Indian Society of Medical and Pediatric Oncology. Voting was based on scientific evidence and was independent of current treatment practices, drug access restrictions and reimbursement decisions in the represented countries. Drug access and reimbursement across Asia are discussed separately in the manuscript. The Pan-Asian consensus aims to guide the optimisation and harmonisation of management of patients with EOC in Asia, drawing on the evidence provided by both Western and Asian trials. Attention is drawn to the disparity in the drug approvals and reimbursement strategies between countries.